Disclosed herein are compositions comprising a sophorolipid surfactant and a bio-synergist and the methods of using the same.

The present disclosure relates to a method of separating and purifying sophorolipids having improved physical properties such as unusual odor, color, and viscosity from oxidized and lactonic sophorolipids precipitate produced by culturing the genus Candida yeast fungus.

An -salidroside, a method for preparing same, and application thereof. A novel type of salidroside, namely, -salidroside, which when compared with the known -salidroside, -salidroside exhibits superior activity in scavenging DPPH radicals and hydroxyl radicals and can be added as a new functional ingredient to cosmetics or anti-fatigue health supplements. The method for preparing -salidroside involves using inexpensive starch, etc., as a glycosyl donor and tyrosol as a substrate, synthesizing -salidroside under the action of glycosyltransferase. The glycosyltransferase has strict specificity and chiral catalytic ability, enabling the specific generation of -salidroside.

Provided is a method for improving the yield of rhamnolipids comprising culturing in medium containing a triglyceride containing oil and sweetener as a carbon source.

Provided is a method for improving the yield of rhamnolipids comprising culturing in medium containing a triglyceride containing oil and sweetener as a carbon source.

The present disclosure provides compositions comprising mutant fungi include an inactive form of the sterylglucosidase enzyme. The present disclosure is also directed to vaccine based compositions, which include a mutant fungus that prohibit pathogenic fungal infection. This disclosure also provides methods for administering these compositions as a prophylaxis against fungal infection, as well as methods for isolating sterylglucosides that include the use of such mutant fungal compositions.

The present disclosure provides compositions comprising mutant fungi include an inactive form of the sterylglucosidase enzyme. The present disclosure is also directed to vaccine based compositions, which include a mutant fungus that prohibit pathogenic fungal infection. This disclosure also provides methods for administering these compositions as a prophylaxis against fungal infection, as well as methods for isolating sterylglucosides that include the use of such mutant fungal compositions.

Provided are a method of producing minor ginsenosides using a ginsenoside glycosidase protein derived from a Microbacterium sp. (Microbacterium testaceum) microorganism, and a composition including the protein for conversion into minor ginsenosides. The ginsenoside glycosidase exhibits very excellent activity of specifically hydrolyzing a sugar at the C-6 position of ginsenoside to convert the ginsenoside into in-vivo absorbable minor ginsenoside, thereby being very usefully applied to mass-production of ginsenoside.

Provided are a method of producing minor ginsenosides using a ginsenoside glycosidase protein derived from a Microbacterium sp. (Microbacterium testaceum) microorganism, and a composition including the protein for conversion into minor ginsenosides. The ginsenoside glycosidase exhibits very excellent activity of specifically hydrolyzing a sugar at the C-6 position of ginsenoside to convert the ginsenoside into in-vivo absorbable minor ginsenoside, thereby being very usefully applied to mass-production of ginsenoside.

An object of the present invention is to provide a trans-resveratrol derivative that resists isomerization to the cis-form. Another object of the present invention is to provide a trans-resveratrol derivative that has no toxicity against cells and has sufficient antioxidative properties and/or a sufficient whitening effect. This object can be achieved by a method for producing a trans-resveratrol polysaccharide, the method comprising the step of bringing a trans-resveratrol glucoside into contact with sugar in the presence of -cyclodextrin glucanotransferase.